DUTRENEO: durvalumab and tremelimumab vs chemo

(2:12)

DUTRENEO Trial

(3:)

DANUBE trial: Durvalumab alone or with tremelimumab for metastatic bladder cancer

(4:38)

FDA Approves Durvalumab / Imfinzi for Resectable NSCLC Non-Small Cell Lung Cancer

(2:43)

Combination tremelimumab and durvalumab in HCC

(7:47)

POSEIDON: durvalumab +/- tremelimumab + chemo in 1L mNSCLC

(3:48)

NIAGARA: perioperative durvalumab with neoadjuvant chemotherapy in MIBC

(2:26)

Durvalumab (Imfinzi): How It Works, Benefits, and Side Effects Explained

(2:15)

Durvalumab after #Chemoradiotherapy in Stage III Non-Small-Cell Lung #Cancer. | #MedicalVideos

(2:32)

INMUNOTERAPIA EN CANCER DE VEJIGA - Dr. Tinajero Juan Diego-

(40:42)

How is Immunotherapy Used to Fight Cancer? | Dana-Farber Cancer Institute | Science Illustrated

(2:44)

No benefit for adjuvant durvalumab in completely resected NSCLC

(6:35)

Stage III NSCLC: When to Start Durvalumab

(6:6)

Durvalumab improves PFS in stage III lung cancer

(6:48)

HIMALAYA: tremelimumab + durvalumab in unresectable HCC

(4:56)

Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer

(6:4)

Discovering the PD-1 Checkpoint: Winners of the 2014 William B. Coley Award for Tumor Immunology

(3:40)

Uro Oncology Section of USI Webinar - 24th April 2023

(1:14:8)

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC

(7:48)

Durvalumab as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer

(4:39)

Durvalumab after chemoradiotherapy improves overall survival in lung cancer patients

(2:56)

Dr. Langer on the Benefit of Durvalumab in Stage III NSCLC

(2:10)

Double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in NSCLC

(43)

Durvalumab: the new standard of care for NSCLC?

(1:24)

[lung]The role of durvalumab in patients with stage 3 lung cancer in a real hospital

(3:53)

Dr. Simon on Durvalumab for Patients With Lung Cancer

(1:20)

EMERALD-1: durvalumab, bevacizumab and TACE in unresectable HCC

(1:34)

Results for Durvalumab in the Second-Line Treatment of NSCLC

(1:37)

Trial of durvalumab for bladder cancer

(1:)

Dr. Feldman on Durvalumab for Patients With Lung Cancer

(47)